Epidermal growth factor inhibition in solid tumours

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

The epidermal growth factor receptor (EGFR) plays an important role in the carcinogenesis of many human malignancies and is therefore an attractive target against which anticancer therapy may be effective. At present, there are two ways in which this may be achieved clinically: antibodies against EGFR and inhibitors of the EGFR tyrosine kinase. This review describes presently approved agents cetuximab (monoclonal EGFR antibody), gefitinib and erlotinib (EGFR tyrosine kinase inhibitors) in detail. Efficacy data for these agents in various human malignancies is presented. Various other agents that are in the early stages of development at present have also been mentioned.

Original languageEnglish (US)
Pages (from-to)1165-1174
Number of pages10
JournalExpert Opinion on Biological Therapy
Volume5
Issue number9
DOIs
StatePublished - Sep 1 2005

Fingerprint

Epidermal Growth Factor Receptor
Epidermal Growth Factor
Tumors
Neoplasms
Protein-Tyrosine Kinases
Antibodies
Carcinogenesis
Therapeutics

Keywords

  • Cetuximab
  • EGFR antibodies
  • EGFR inhibitors
  • EGFR tyrosine kinase inhibitors
  • Erlotinib
  • Gefitinib

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Epidermal growth factor inhibition in solid tumours. / Ganti, Apar Kishor P; Potti, Anil.

In: Expert Opinion on Biological Therapy, Vol. 5, No. 9, 01.09.2005, p. 1165-1174.

Research output: Contribution to journalReview article

@article{c7e3369835e24a05899b472c67fa4e1c,
title = "Epidermal growth factor inhibition in solid tumours",
abstract = "The epidermal growth factor receptor (EGFR) plays an important role in the carcinogenesis of many human malignancies and is therefore an attractive target against which anticancer therapy may be effective. At present, there are two ways in which this may be achieved clinically: antibodies against EGFR and inhibitors of the EGFR tyrosine kinase. This review describes presently approved agents cetuximab (monoclonal EGFR antibody), gefitinib and erlotinib (EGFR tyrosine kinase inhibitors) in detail. Efficacy data for these agents in various human malignancies is presented. Various other agents that are in the early stages of development at present have also been mentioned.",
keywords = "Cetuximab, EGFR antibodies, EGFR inhibitors, EGFR tyrosine kinase inhibitors, Erlotinib, Gefitinib",
author = "Ganti, {Apar Kishor P} and Anil Potti",
year = "2005",
month = "9",
day = "1",
doi = "10.1517/14712598.5.9.1165",
language = "English (US)",
volume = "5",
pages = "1165--1174",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Elsevier BV",
number = "9",

}

TY - JOUR

T1 - Epidermal growth factor inhibition in solid tumours

AU - Ganti, Apar Kishor P

AU - Potti, Anil

PY - 2005/9/1

Y1 - 2005/9/1

N2 - The epidermal growth factor receptor (EGFR) plays an important role in the carcinogenesis of many human malignancies and is therefore an attractive target against which anticancer therapy may be effective. At present, there are two ways in which this may be achieved clinically: antibodies against EGFR and inhibitors of the EGFR tyrosine kinase. This review describes presently approved agents cetuximab (monoclonal EGFR antibody), gefitinib and erlotinib (EGFR tyrosine kinase inhibitors) in detail. Efficacy data for these agents in various human malignancies is presented. Various other agents that are in the early stages of development at present have also been mentioned.

AB - The epidermal growth factor receptor (EGFR) plays an important role in the carcinogenesis of many human malignancies and is therefore an attractive target against which anticancer therapy may be effective. At present, there are two ways in which this may be achieved clinically: antibodies against EGFR and inhibitors of the EGFR tyrosine kinase. This review describes presently approved agents cetuximab (monoclonal EGFR antibody), gefitinib and erlotinib (EGFR tyrosine kinase inhibitors) in detail. Efficacy data for these agents in various human malignancies is presented. Various other agents that are in the early stages of development at present have also been mentioned.

KW - Cetuximab

KW - EGFR antibodies

KW - EGFR inhibitors

KW - EGFR tyrosine kinase inhibitors

KW - Erlotinib

KW - Gefitinib

UR - http://www.scopus.com/inward/record.url?scp=24144461280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144461280&partnerID=8YFLogxK

U2 - 10.1517/14712598.5.9.1165

DO - 10.1517/14712598.5.9.1165

M3 - Review article

C2 - 16120047

AN - SCOPUS:24144461280

VL - 5

SP - 1165

EP - 1174

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 9

ER -